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ABSTRACT
Introduction: The impact of crisaborole oint-
ment, a nonsteroidal phosphodiesterase 4 inhibi-
tor for the treatment of mild to moderate atopic
dermatitis (AD), on quality of life (QoL) was
assessed in two identically designedphase 3 studies
(AD-301: NCT02118766; AD-302: NCT02118792,
both at http://www.clinicaltrials.gov).
Methods: In both studies, patients aged
C 2 years with mild to moderate AD per the
Investigator’s Static Global Assessment were
randomly assigned 2:1 to receive crisaborole or
vehicle twice daily for 28 days. QoL was assessed
using the Children’s Dermatology Life Quality
Index (CDLQI) (2–15 years), the Dermatology
Life Quality Index (DLQI) (C 16 years), and the
Dermatitis Family Impact Questionnaire (DFI)
(parents/caregivers/family of patients aged
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2–17 years). Established QoL score severity
bands provided clinical context.
Results: Greater mean improvement in QoL
was observed in crisaborole-treated patients
than in vehicle-treated patients at day 29 [mean
change from baseline (DBL), CDLQI: - 4.6 vs.
- 3.0; P\ 0.001; DLQI: - 5.2 vs. - 3.5;
P = 0.015]. At baseline, more than half the
patients had a ‘‘moderate effect’’ or higher of AD
on QoL. At day 29, there was a trend toward
more crisaborole- than vehicle-treated patients
having ‘‘small effect’’ to ‘‘no effect’’, The QoL of
parents/caregivers/family improved more for
crisaborole-treated than for vehicle-treated
patients (DBL, DFI: - 3.7 vs. - 2.7; P = 0.003).
Conclusion: Crisaborole treatment results in
clinically meaningful improvement in QoL for
patients and their parents/caregivers/families.
Trial Registration: AD-301: http://www.clini
caltrials.gov, NCT02118766; AD-302: http://www.
clinicaltrials.gov, NCT02118792.
Funding: Anacor Pharmaceuticals, Inc., a
wholly owned subsidiary of Pfizer Inc., New
York, NY.
Keywords: Atopic dermatitis; Crisaborole; Ecz-
ema; PDE4; Phosphodiesterase 4; Quality of life;
Topical treatment
INTRODUCTION
Atopic dermatitis (AD), a chronic inflammatory
skin disorder [1–3], affects an estimated 15–30%
of children and 2–10% of adults worldwide
[1, 4]. The clinical symptoms and visible skin
lesions of AD are often associated with psycho-
logic and psychosocial comorbidities and neg-
atively impact the quality of life (QoL) of
patients and their families [2, 4–7]. In addition,
the hallmark symptom of AD—pruritus—con-
tributes to sleep dysfunction and reduced QoL
[2, 8].
Treatment of AD with topical calcineurin
inhibitors (TCIs) or topical corticosteroids
(TCSs), recommended by the current treatment
guidelines [9, 10], reduces disease severity and is
associated with improved QoL for patients and
their caregivers [11–13]. However, the potential
impact of TCS treatment on patient QoL is often
not realized because of well-documented ‘‘ster-
oid phobia’’ in the majority of caregivers, lead-
ing to underdosing, decreased patient and
caregiver adherence, and reduced QoL [14].
Crisaborole ointment is a nonsteroidal
phosphodiesterase 4 (PDE4) inhibitor for the
treatment of mild to moderate AD [15–20].
Previously published results from two large,
vehicle-controlled, identically designed, phase
3 clinical studies in patients C 2 years of age
with mild to moderate AD showed that signifi-
cantly more crisaborole-treated patients
achieved global disease severity assessments of
‘‘clear’’ or ‘‘almost clear’’, improvement in all
assessed symptoms of AD, and lessening of
pruritus severity by the end of treatment [20].
These improvements in global disease severity,
symptoms of AD, and severity of pruritus can
improve the QoL of patients and their families
[6]. To better understand how these improve-
ments in clinical endpoints in the two phase 3
clinical studies translate to improvements in
the QoL of patients and their families, the
impact of crisaborole ointment on QoL of
patients C 2 years old and the parents/care-
givers/families of patients 2–17 years old in
these two studies was assessed.
METHODS
Study Design and Treatment
Two multicenter, randomized, double-blind,
vehicle-controlled, phase 3 studies (http://www.
clinicaltrials.gov; AD-301: NCT02118766; AD-
302: NCT02118792) were conducted to assess
the efficacy and safety of crisaborole in patients
C 2 years old with mild to moderate AD; the
efficacy and safety results from these studies
have been published [20]. Patients were ran-
domly assigned 2:1 to receive crisaborole oint-
ment, 2% (Pfizer Inc., New York, NY), or
vehicle, applied twice daily for 28 days (Fig. 1).
Both studies were developed and conducted in
accordance with the principles of Good Clinical
Practice and relevant country-specific regula-
tory requirements, and the protocols were
approved by an institutional review board at
each site. All procedures followed were in
606 Dermatol Ther (Heidelb) (2018) 8:605–619
accordance with the ethical standards of the
responsible committee on human experimen-
tation (institutional and national) and with the
Helsinki Declaration of 1964, as revised in 2013.
Informed consent was obtained from all
patients for being included in the study.
Patients
At baseline/day 1, patients had to be C 2 years
old with a clinical diagnosis of AD per the
Hanifin and Rajka criteria [21], have C 5%
treatable body surface area (BSA) involvement,
and have an Investigator’s Static Global Assess-
ment (ISGA) score of mild (2) or moderate (3),
assessed on a 5-point scale from clear (0) to
severe (4). Key exclusion criteria were unsta-
ble AD, the consistent need for TCSs, history of
anaphylaxis or angioedema, history of biologic
therapy, history of recent use of systemic or
topical therapies, involvement in another drug
or device research study in the preceding
30 days, or known sensitivity to any crisaborole
component. The enrolled patient population
reflected the overall population with AD, with
at least 20% of patients between the ages of 2
and 6 years and no more than 15% adults.
QoL Assessments
Validated QoL scales for inflammatory skin
diseases were used for assessments at base-
line/day 1 and day 29 and were based on patient
age at baseline/day 1 (Fig. 2). Patients 2–15 years
of age were assessed using the Children’s Der-
matology Life Quality Index (CDLQI) [22], and
patients aged C 16 years were assessed using the
Dermatology Life Quality Index (DLQI) [23].
Because the CDLQI is only validated for use in
patients as young as 4 years old [22], change in
CDLQI score was also assessed in the group of
patients aged 4–15 years. The validated
Fig. 1 CONSORT flow diagram. Enrollment, randomization, treatment, and follow-up
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Dermatitis Family Impact (DFI) scale was used
to assess the effect of AD on the QoL of par-
ents/caregivers/families of patients 2–17 years
of age [24]. The CDLQI was originally validated
for children aged 4 years and older; therefore,
children younger than 4 years were aided by
parental report. Each scale was descriptively
summarized by treatment group, and change
from baseline/day 1 results were reported.
Fig. 2 Validated QoL assessment scales and subscales. Superscript letter a indicates that subscale analysis for DFI has not
been validated
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Minimal Clinically Important Difference
The minimal clinically important difference
(MCID) is considered the smallest amount of
change in the assessment instrument score that
patients perceive as beneficial and that would
result in a change in patient treatment in the
absence of troublesome side effects and exces-
sive cost [25]. The MCID for the CDLQI used in
this analysis was a C 2.5-point change from
baseline [26]. For the DLQI, a longitudinal study
in patients with inflammatory skin diseases
demonstrated an MCID of C 3.3-point change
from baseline [27]. Additional studies are nec-
essary to validate the observed MCID for the
CDLQI and DLQI in patients with AD. The
MCID for the DFI questionnaire has not been
established [24].
CDLQI and DLQI Severity Bands
Severity bands provide clinical interpretation of
individual CDLQI and DLQI scores [28]. The
effect on the child’s life associated with CDLQI
scores was defined as 0–1 = ‘‘no effect,’’ 2–
6 = ‘‘small effect,’’ 7–12 = ‘‘moderate effect,’’
13–18 = ‘‘very large effect,’’ and 19–30 = ‘‘ex-
tremely large effect’’ [28]. Severity bands for
patients C 16 years of age for DLQI scores were
defined as 0–1 = ‘‘no effect,’’ 2–5 = ‘‘small
effect,’’ 6–10 = ‘‘moderate effect,’’ 11–20 = ‘‘very
large effect,’’ and 21–30 = ‘‘extremely large
effect’’ [29].
Statistics
Analysis of QoL measurements was performed
using descriptive statistics. Differences between
treatment groups in absolute change from
baseline were analyzed by Wilcoxon rank sum
test, a nonparametric test. Differences between
treatment groups regarding the percentage of
patients who experienced MCID for the CDLQI
and DLQI at day 29 were analyzed using the
Fisher exact test. A Wilcoxon rank sum test was
used to analyze differences between treatment
groups in severity bands.
RESULTS
Patient Disposition and Characteristics
Studies AD-301 and AD-302 enrolled 1016
patients treated with crisaborole and 506
patients treated with vehicle, with the first
patient enrolling in March 2014 and the last
visit occurring in April 2015. No significant
differences were observed in baseline demo-
graphics and disease characteristics across
treatment groups (Table 1). The enrolled patient
population reflected the overall AD population,
with 85% of patients experiencing symptoms
before 5 years of age [3]. Most of the enrolled
patient population was 2–15 years old (crisa-
borole: 80.2%; vehicle: 81.4%), and approxi-
mately one-fifth of the enrolled population was
C 16 years of age (crisaborole: 19.8%; vehicle:
18.6%). The severity of pruritus and QoL
assessment were similar across treatment groups
at baseline.
Overall QoL Assessment and MCID at Day
29
Overall, children in both the vehicle and the
crisaborole groups experienced improvement in
QoL during the study. Children and adolescents
aged 2–15 years in the crisaborole ointment
group showed greater mean reduction in QoL
assessment at day 29 than patients given vehi-
cle, as assessed by CDLQI (mean change from
baseline, crisaborole: - 4.6; vehicle: - 3.0;
P\ 0.001) (Fig. 3a). Among the subgroup of
patients aged 4–15 years, results were numeri-
cally similar and retained statistical significance
(mean change from baseline, crisaborole: - 4.5;
vehicle: - 2.6; P\ 0.001) (Fig. 3b). More crisa-
borole-treated patients (61.7%) achieved MCID,
defined as a C 2.5-point change from baseline
for CDLQI [26], than vehicle-treated patients
(52.1%) (P = 0.003).
Patients C 16 years of age treated with crisa-
borole ointment showed greater mean reduc-
tion in DLQI scores at day 29 than patients
given vehicle (mean change from baseline,
crisaborole: - 5.2; vehicle: - 3.5; P = 0.015)
(Fig. 3c). MCID, defined as a C 3.3-point change
Dermatol Ther (Heidelb) (2018) 8:605–619 609
Table 1 Baseline patient characteristics and disease characteristics by age group in crisaborole phase 3 studies (ITT
population)
Patient demographics and
characteristics
Ages 2–15 years Ages ‡ 16 years
Vehicle
(n = 412)
Crisaborole ointment
(n = 815)
Vehicle
(n = 94)
Crisaborole ointment
(n = 201)
Sex, %
Male 47.6 46.9 30.9 33.8
Female 52.4 53.1 69.1 66.2
Ethnicity, %
Hispanic or Latino 21.4 20.9 13.8 14.9
Not Hispanic or Latino 78.6 79.1 86.2 85.1
Race, %
American Indian or Alaskan
Native
0.7 1.0 2.1 1.5
Asian 4.4 4.8 9.6 6.5
Black or African American 26.2 27.4 33.0 30.8
Hawaiian or other Pacific
Islander
1.7 0.7 1.1 0.5
White 61.9 61.7 54.3 56.7
Other 5.1 4.4 0.0 4.0
Severity of pruritus scale, n (%)
0—none 14 (3.9) 31 (4.3) 5 (6.0) 4 (2.3)
1—mild 102 (28.5) 185 (25.4) 17 (20.5) 44 (25.0)
2—moderate 137 (38.3) 253 (34.8) 30 (36.1) 78 (44.3)
3—severe 105 (29.3) 258 (35.5) 31 (37.3) 50 (28.4)
CDLQI
n 403 797 – –
Mean (SD) 9.0 (6.02) 9.3 (5.99) – –
DLQI
n – – 92 192
Mean (SD) – – 9.3 (6.55) 9.7 (6.29)
DFI (parents/caregivers/families of patients ages 2–17 years)
n 431 862 – –
Mean (SD) 7.8 (6.17) 8.1 (6.61) – –
CDLQI Children’s Dermatology Life Quality Index, DLQI Dermatology Life Quality Index, DFI Dermatitis Family Impact
Questionnaire, ITT intent-to-treat, SD standard deviation
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Fig. 3 Mean change from baseline in a CDLQI ages 2–15 years, b CDLQI ages 4–15 years, c DLQI, and d DFI scores
(pooled analysis, ITT population)
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from baseline [27], was achieved by 53.9% of
crisaborole-treated patients and 41.5% of vehi-
cle-treated patients (P = 0.083). Assessment of
improvement in QoL for the parents, caregivers,
and families of children and adolescents with
AD showed that crisaborole-treated patients
showed greater mean reduction overall (mean
change from baseline, crisaborole: - 3.7; vehi-
cle: - 2.7; P = 0.003) (Fig. 3d).
Severity Bands for CDLQI and DLQI
To provide clinical context to CDLQI and DLQI
scores, established severity bands ranging from
‘‘no effect’’ to an ‘‘extremely large effect’’ were
analyzed. Most children and adolescents expe-
rienced a ‘‘moderate effect’’ of AD on QoL at
baseline (crisaborole: 35.3%; vehicle: 34.0%) or
worse (crisaborole: 27.2%; vehicle: 24.6%;
P = 0.1769) (Fig. 4a). By day 29, crisaborole
Fig. 4 Severity bands for a CDLQI and b DLQI overall (pooled analysis, ITT population)
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treatment led to an improvement in QoL, with
75.5% of patients reporting that their AD had
‘‘small effect’’ to ‘‘no effect,’’ compared with
64.9% of vehicle-treated patients (P = 0.0002).
For patients C 16 years of age, most reported
that AD had a ‘‘moderate effect’’ on QoL at
baseline (crisaborole: 29.7%; vehicle: 29.3%) or
worse (crisaborole: 39.1%; vehicle: 34.8%;
P = 0.4030) (Fig. 4b). By day 29, a numerically
greater proportion of crisaborole-treated
patients reported that AD had ‘‘small effect’’ to
‘‘no effect’’ (71.8%) than vehicle-treated
patients (65.5%; P = 0.1400). These data indi-
cate an overall reduction in the impact of AD on
the lives of patients, especially for those who
received crisaborole ointment.
Table 2 Responses per question for CDLQI (ITT population)
Question Treatment Patients per response, % P valuea,b
Not at all Only a little Quite a lot Very much
Itching/scratching, painful/sore Vehicle 13.5 48.9 24.9 12.7 \ 0.001
Crisaborole ointment 18.6 57.9 17.1 6.4
Embarrassed/self-conscious Vehicle 61.0 23.8 10.5 4.7 0.011
Crisaborole ointment 68.2 21.2 7.7 2.9
Affected friendships Vehicle 90.1 6.1 2.2 1.7 0.241
Crisaborole ointment 92.0 6.6 0.8 0.7
Affected clothing Vehicle 61.3 24.6 8.8 5.2 0.210
Crisaborole ointment 64.2 25.6 6.7 3.6
Playing Vehicle 62.4 26.8 6.6 4.1 0.010
Crisaborole ointment 69.5 23.8 4.5 2.2
Sports Vehicle 74.0 16.0 5.2 4.7 0.205
Crisaborole ointment 77.6 13.9 3.8 4.7
School time Vehicle 75.0 15.9 6.9 2.2 0.155
Crisaborole ointment 79.1 16.1 3.1 1.7
Holiday time Vehicle 61.2 25.9 5.8 7.2 0.039
Crisaborole ointment 69.9 22.7 6.0 1.3
Teasing/bullying Vehicle 82.8 11.9 3.6 1.7 0.210
Crisaborole ointment 85.5 11.2 1.8 1.4
Child sleep Vehicle 42.3 34.5 13.5 9.7 0.001
Crisaborole ointment 51.4 33.0 9.3 6.2
Burden of treatment Vehicle 49.7 34.5 11.0 4.7 0.001
Crisaborole ointment 60.2 29.2 7.4 3.3
CDLQI Children’s Dermatology Life Quality Index, ITT intent-to-treat
a P value from a Wilcoxon rank sum test with factor of treatment group
b Italic rows indicate statistically significant difference in question response between crisaborole and vehicle treatment
groups
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CDLQI, DLQI, and DFI: Question Level
Analysis
Compared with vehicle-treated patients, more
children and adolescents treated with crisabor-
ole ointment experienced less impact on QoL
related to itching/scratching and painful/sore
(P\0.001), feelings of embarrassment and self-
consciousness (P = 0.011), playing (P = 0.010),
holiday time (P = 0.039), sleep (P = 0.001), and
the burden of treatment (P = 0.001) (Table 2).
Similarly, more crisaborole-treated patients
than vehicle-treated patients C 16 years of age
reported less impact on QoL for itching/
scratching and painful/sore (P = 0.001), embar-
rassment and self-consciousness (P = 0.024),
and sexual difficulties between partners
(P = 0.017) (Table 3). The parents/care-
givers/families of patients 2–17 years of age
treated with crisaborole experienced greater
Table 3 Responses per question for DLQI (ITT population)
Question Treatment Patients per response, % P valuea,b
Not at all Only a little Quite a lot Very much
Itching/scratching, painful/sore Vehicle 8.3 65.5 16.7 9.5 0.001
Crisaborole ointment 27.1 56.4 12.2 4.3
Embarrassed/self-conscious Vehicle 47.6 25.0 11.9 15.5 0.024
Crisaborole ointment 56.9 31.4 6.9 4.8
Shopping, home, yard activities Vehicle 81.0 13.1 2.4 3.6 0.391
Crisaborole ointment 75.5 19.7 3.7 1.1
Influenced clothes worn Vehicle 47.6 25.0 9.5 17.9 0.063
Crisaborole ointment 55.9 27.1 11.2 5.9
Affected social/leisure activity Vehicle 70.2 17.9 6.0 6.0 0.366
Crisaborole ointment 73.9 20.7 3.7 1.6
Affected sports participation Vehicle 79.8 16.7 0.0 3.6 0.556
Crisaborole ointment 83.0 12.2 3.7 1.1
Affected work/studying Vehicle 70.2 23.8 3.6 2.4 0.193
Crisaborole ointment 78.7 13.8 1.6 5.9
Affected relationships Vehicle 75.0 21.4 1.2 2.4 0.263
Crisaborole ointment 80.9 17.0 1.1 1.1
Sexual difficulties Vehicle 86.9 10.7 0.0 2.4 0.017
Crisaborole ointment 95.2 3.2 0.5 1.1
Burden of treatment Vehicle 67.9 27.4 2.4 2.4 0.164
Crisaborole ointment 59.6 31.4 9.0 0.0
DLQI Dermatology Life Quality Index, ITT intent-to-treat
a P value from a Wilcoxon rank sum test with factor of treatment group
b Italic rows indicate statistically significant difference in question response between crisaborole and vehicle treatment
groups
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improvement than those of vehicle-treated
patients in the categories of sleep (P = 0.015),
time shopping (P = 0.026), and expenditure
(P = 0.042) (Table 4).
DISCUSSION
The current study revealed that even mild AD
can significantly affect patients and their fami-
lies [30]; therefore, regardless of severity of AD,
treatment can improve QoL for patients and
their families. Crisaborole-treated patients
showed greater reduction in pruritus severity
than vehicle-treated patients [20] and a reduc-
tion in the impact of itching and scratching on
QoL for children, adolescents, and adults. AD-
associated pruritus greatly affects patient and
caregiver QoL and results in sleep disruption
[2, 8]. Sleep disruption strongly affects the QoL
of children and adults [31], and it is linked to
the development of the mental health
Table 4 Responses per question for DFI (ITT population)
Question Treatment Patients per response, % P valuea,b
Not at all Only a little Quite a lot Very much
Housework Vehicle 61.5 29.6 6.0 2.9 0.555
Crisaborole ointment 63.6 27.4 5.7 3.3
Food Vehicle 73.8 18.8 4.7 2.6 0.142
Crisaborole ointment 77.5 17.2 3.5 1.8
Sleep Vehicle 56.8 27.6 8.4 7.1 0.015
Crisaborole ointment 64.2 22.8 8.5 4.5
Leisure Vehicle 66.2 23.8 5.8 4.2 0.281
Crisaborole ointment 68.7 24.2 3.8 3.3
Time shopping Vehicle 78.3 18.6 1.8 1.3 0.026
Crisaborole ointment 83.7 13.7 1.6 1.1
Expenditure Vehicle 63.4 29.3 5.0 2.4 0.042
Crisaborole ointment 69.9 23.4 5.0 2.0
Tiredness Vehicle 60.2 27.7 7.3 4.7 0.019
Crisaborole ointment 67.2 22.9 6.2 3.7
Emotional distress Vehicle 58.6 29.8 8.9 2.6 0.191
Crisaborole ointment 63.1 25.9 7.3 3.7
Relationships Vehicle 76.7 17.8 4.5 1.0 0.117
Crisaborole ointment 80.8 14.4 3.3 1.6
Burden of treatment Vehicle 46.5 36.0 13.4 4.2 0.201
Crisaborole ointment 49.0 37.8 9.0 4.3
DFI Dermatitis Family Impact Questionnaire, ITT intent-to-treat
a P value from a Wilcoxon rank sum test with factor of treatment group
b Italic rows indicate statistically significant difference in question response between crisaborole and vehicle treatment
groups
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comorbidities often seen in patients with AD
[32]. Although additional studies are necessary
to fully assess the impact of crisaborole on sleep
quality, crisaborole-treated children and ado-
lescents and their families experienced lessen-
ing of the impact of AD on sleep.
The visibility and stigma associated with skin
diseases also impacts the QoL of patients [2].
The reduction in feelings of embarrassment and
self-consciousness for crisaborole-treated
patients most likely results from reduction in
global disease severity and diminution of
lesions in visible areas [20]. Treatment of AD
itself imposes a significant burden on the QoL
of patients because treatment regimens are
often time consuming and associated with life-
style changes [2, 11, 33, 34]. Greater disease
severity is directly correlated with more time
spent on treatment [34]. A greater proportion of
crisaborole-treated children and adolescents
experienced lessening of the burden of treat-
ment, which might have resulted from reduc-
tion in pruritus severity and global disease
severity [20]. AD also has a significant impact
on the QoL of parents/caregivers/families of
patients with AD because parents spend several
hours each day dealing with treatment and lose
1–2 h of sleep on average each night [2, 30]. The
lessening of the impact of AD on sleep reported
by the parents/caregivers/families of crisabor-
ole-treated patients might reduce sleep loss-
associated side effects, such as decreased coping
skills and poor work functioning [2].
Available treatments, such as TCSs and TCIs,
improve QoL for patients and their families. A
greater mean reduction in the Parents of Chil-
dren With Atopic Dermatitis (PQoL-AD) score
was observed for pimecrolimus-treated patients
2–17 years of age with mild to moderate AD
treated with pimecrolimus for 6 weeks (least-
squares mean change, - 3.2) compared with
vehicle-treated patients (- 1.63; P = 0.023) [12].
The current study showed that, similar to TCS
and TCI, crisaborole ointment improves QoL for
patients and their caregivers. Direct comparison
of TCS and TCI studies with those of crisaborole
are not feasible because of the lack of head-to-
head trials and differences in study design,
assessment tools used, and patient populations
in the individual studies. The large ‘‘vehicle
effect’’ seen with the pimecrolimus study and in
the current study is commonly observed in AD
clinical trials. Topical vehicle is not a placebo,
and emollients are the foundation of step care
in management of AD [35]. Use of emollients
reduces the need for topical steroids in children
[36], and emollient therapy is a prevention
strategy in high-risk neonates [37]. Petrolatum,
a common moisturizer and the main compo-
nent of the base for the crisaborole ointment
and the vehicle ointment, has skin barrier repair
and immune-modulating properties [38]. Com-
pared with vehicle alone, the addition of crisa-
borole improves QoL for patients with AD and
their parents/caregivers/families.
Potential limitations with these studies
include the use of CDLQI and DLQI in AD
because, although both measurement tools are
validated for inflammatory skin diseases and
commonly used in AD trials, these measures are
not specific for AD and might not fully capture
the impact of the disease [39, 40]. In addition,
the CDLQI has been validated in patients
4 years or older only [22]; therefore, younger
patients were aided by a parent/caregiver.
However, analysis of the subgroup aged 4–
15 years showed a change in CDLQI similar to
that seen in the cohort aged 2–15 years.
CONCLUSIONS
Despite the limitations of the study, the
improvements in QoL described herein
demonstrate that the reduction in objective
lesion severity observed in previous analysis
[16–18, 20] is clinically meaningful for patients
and their families. Crisaborole is a promising
novel topical AD treatment that improves mild
to moderate AD and the lives of affected
patients and their families.
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